Clinical Trials - CANF

NCT IDTitleStatusPhasesStart DateCompletion DatePrimary Completion Date
NCT06643260A Phase 3 Study in Moderate-to-Severe Plaque Psoriasis With Piclidenoson to Study Safety and EfficacyNOT_YET_RECRUITINGPHASE32025-062028-062027-12
NCT06387342Namodenoson Treatment of Advanced Pancreatic CancerRECRUITINGPHASE22024-11-102026-12-152026-07-15
NCT05201404Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 CirrhosisRECRUITINGPHASE32023-03-152026-102026-02
NCT04697810Namodenoson in the Treatment of Non-Alcoholic Steatohepatitis (NASH)RECRUITINGPHASE22021-12-102025-10-152025-04-15
NCT04333472Piclidenoson for Treatment of COVID-19COMPLETEDPHASE22021-01-062022-04-212022-03-06
NCT01905124Safety &Efficacy of CF101 to Subjects With UveitisWITHDRAWNPHASE22019-012019-102019-09
NCT00837291A Study of the Efficacy and Safety of CF101 to Patients With Osteoarthritis of the KneeWITHDRAWNPHASE22018-112019-012018-12
NCT03168256CF101 Therapy in Patients With Moderate-to-severe Plaque PsoriasisCOMPLETEDPHASE32018-09-152022-04-272022-01-06
NCT02927314A Study of the Efficacy and Safety of CF102 in the Treatment of Non-Alcoholic Fatty Liver DiseaseCOMPLETEDPHASE22017-11-272020-03-012020-03-01
NCT02647762CF101 Therapy Compared to Methotrexate Therapy for Active Rheumatoid ArthritisTERMINATEDPHASE32017-10-302020-11-302020-11-30
NCT02128958Phase 2, Randomized, Double-Blind, Placebo-Controlled of the Efficacy and Safety of CF102 in Hepatocellular Carcinoma (HCC)COMPLETEDPHASE22014-092021-12-312017-11-27
NCT01235234Trial of CF101 to Treat Patients With Dry Eye DiseaseCOMPLETEDPHASE32011-072013-122013-11
NCT01265667Trial of CF101 to Treat Patients With PsoriasisCOMPLETEDPHASE2, PHASE32011-072015-052015-03
NCT01033422Safety and Efficacy of Daily CF101 Administered Orally in Subjects With Elevated Intraocular PressureCOMPLETEDPHASE22010-102017-042016-12
NCT01034306Oral CF101 Tablets Treatment in Patients With Rheumatoid ArthritisCOMPLETEDPHASE22010-102013-122013-12
NCT00790673A Phase 1/2 Study of CF102 in Patients With Chronic Hepatitis C Genotype 1COMPLETEDPHASE1, PHASE22009-072011-072011-06
NCT00790218A Phase 1-2 Study of CF102 in Patients With Advanced Hepatocellular CarcinomaCOMPLETEDPHASE1, PHASE22009-022013-122012-12
NCT00556894Oral CF101 Tablets and Methotrexate Treatment in Rheumatoid Arthritis PatientsCOMPLETEDPHASE22008-022009-042009-03
NCT00428974Safety and Efficacy Study of CF101 to Treat PsoriasisCOMPLETEDPHASE22007-062009-092009-09
NCT00349466Safety and Efficacy Study of CF101 to Treat Keratoconjunctivitis SiccaCOMPLETEDPHASE22007-012009-052009-05
NCT00280917Oral CF101 and Methotrexate Treatment in Rheumatoid Arthritis PatientsCOMPLETEDPHASE22006-062007-042007-04